Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma

The present randomised phase II study was an effort to evaluate single-agent gemcitabine as a first-line systemic treatment of Asian patients with unresectable hepatocellular carcinoma (HCC). Gemcitabine was given via intravenous infusion at 1250 mg m(−2) on days 1 and 8 of 3-week cycles. Patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Guan, Z, Wang, Y, Maoleekoonpairoj, S, Chen, Z, Kim, W S, Ratanatharathorn, V, Reece, W H H, Kim, T W, Lehnert, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394454/
https://www.ncbi.nlm.nih.gov/pubmed/14612894
http://dx.doi.org/10.1038/sj.bjc.6601369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394454/
https://www.ncbi.nlm.nih.gov/pubmed/14612894
http://dx.doi.org/10.1038/sj.bjc.6601369

Ejemplares similares